FI113769B - Neuroskyddande kromanföreningar - Google Patents

Neuroskyddande kromanföreningar Download PDF

Info

Publication number
FI113769B
FI113769B FI950403A FI950403A FI113769B FI 113769 B FI113769 B FI 113769B FI 950403 A FI950403 A FI 950403A FI 950403 A FI950403 A FI 950403A FI 113769 B FI113769 B FI 113769B
Authority
FI
Finland
Prior art keywords
hydroxy
compound
fluorophenyl
chroman
piperidin
Prior art date
Application number
FI950403A
Other languages
English (en)
Finnish (fi)
Other versions
FI950403A0 (sv
FI950403A (sv
Inventor
Bertrand L Chenard
Todd W Butler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI950403A0 publication Critical patent/FI950403A0/sv
Publication of FI950403A publication Critical patent/FI950403A/sv
Application granted granted Critical
Publication of FI113769B publication Critical patent/FI113769B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (5)

1. Förening, kännetecknad av att den är (3R*, 4S*)-3-[4-(4 - fluorfenyl)-4-hydroxi-piperidin-l-yl]- 5 kroman-4,7-diol, optiska isomerer och farmaceutiskt godtagbara salter därav.
2. Förening enligt patentkrav 1, kanne- tecknad av att föreningen är racemisk (3R*, 4S*)-3- [4-(4-fluorfenyl)-4-hydroxi-piperidin-l-yl]kroman-4,7- 10 diol.
3. Förening enligt patentkrav 1, kanne- tecknad av att föreningen är ( + ) - (3R, 4S)-3-[4-(4- fluorfenyl)-4-hydroxi-piperidin-l-yl]kroman-4,7-diol.
4. Förening enligt patentkrav 1, k ä n n e - 15 tecknad av att föreningen är (-)-(4R, 3S)-3-[4-(4- fluorfenyl)-4-hydroxi-piperidin-l-yl]kroman-4,7-diol.
5. Förening enligt patentkrav 1, k ä n n e - tecknad av att föreningen är ( + ) - (3R, 4S)-3-[4-(4- | fluorfenyl)-4-hydroxi-piperidin-l-yl]kroman-4,7-dioltar- 20 tratetanolathydrat. * : x » t * ! t
FI950403A 1994-01-31 1995-01-30 Neuroskyddande kromanföreningar FI113769B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31
US18947994 1994-01-31

Publications (3)

Publication Number Publication Date
FI950403A0 FI950403A0 (sv) 1995-01-30
FI950403A FI950403A (sv) 1995-08-01
FI113769B true FI113769B (sv) 2004-06-15

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950403A FI113769B (sv) 1994-01-31 1995-01-30 Neuroskyddande kromanföreningar

Country Status (27)

Country Link
US (1) US5744483A (sv)
EP (1) EP0741724B1 (sv)
JP (1) JP2866743B2 (sv)
CN (1) CN1048247C (sv)
AT (1) ATE183184T1 (sv)
AU (1) AU684568B2 (sv)
BR (2) BR9408506A (sv)
CA (1) CA2182101C (sv)
CO (1) CO4230161A1 (sv)
CZ (1) CZ286757B6 (sv)
DE (1) DE69420053T2 (sv)
DK (1) DK0741724T3 (sv)
EG (1) EG20672A (sv)
ES (1) ES2134361T3 (sv)
FI (1) FI113769B (sv)
GR (1) GR3031356T3 (sv)
HU (1) HU221633B1 (sv)
IL (1) IL112415A (sv)
MY (1) MY111623A (sv)
NO (1) NO309190B1 (sv)
NZ (1) NZ275151A (sv)
PE (1) PE43795A1 (sv)
PL (1) PL179448B1 (sv)
RU (1) RU2126404C1 (sv)
TW (1) TW449591B (sv)
WO (1) WO1995020587A1 (sv)
ZA (1) ZA95692B (sv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010240A1 (en) * 1995-09-15 1997-03-20 Pfizer Inc. Phenol derivatives with pharmaceutical activity
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
CA2628173A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
AU2007207481B2 (en) * 2006-01-20 2012-08-23 Merck Sharp & Dohme Corp. Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
EP2522647B1 (en) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Process of separating chiral isomers of chroman compounds and their derivatives and precursors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (sv) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0076075B1 (en) * 1981-09-25 1986-11-20 Beecham Group Plc Pharmaceutically active benzopyran compounds
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1991012005A1 (en) * 1990-02-06 1991-08-22 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
ES2134361T3 (es) 1999-10-01
NO963186L (no) 1996-07-30
EP0741724B1 (en) 1999-08-11
PE43795A1 (es) 1995-12-09
JP2866743B2 (ja) 1999-03-08
PL179448B1 (pl) 2000-09-29
NO309190B1 (no) 2000-12-27
DE69420053D1 (de) 1999-09-16
PL315681A1 (en) 1996-11-25
IL112415A0 (en) 1995-03-30
DE69420053T2 (de) 1999-11-25
JPH09501698A (ja) 1997-02-18
EG20672A (en) 1999-11-30
WO1995020587A1 (en) 1995-08-03
FI950403A0 (sv) 1995-01-30
CZ225696A3 (en) 1997-01-15
ATE183184T1 (de) 1999-08-15
CA2182101A1 (en) 1995-08-03
CN1142825A (zh) 1997-02-12
CA2182101C (en) 1999-08-03
HU9602100D0 (en) 1996-09-30
CN1048247C (zh) 2000-01-12
CZ286757B6 (en) 2000-06-14
ZA95692B (en) 1996-07-30
DK0741724T3 (da) 1999-12-20
MY111623A (en) 2000-09-27
BR9408506A (pt) 1997-08-05
TW449591B (en) 2001-08-11
HUT75942A (en) 1997-05-28
GR3031356T3 (en) 2000-01-31
US5744483A (en) 1998-04-28
EP0741724A1 (en) 1996-11-13
NO963186D0 (no) 1996-07-30
HU221633B1 (hu) 2002-12-28
AU8066394A (en) 1995-08-15
CO4230161A1 (es) 1995-10-19
AU684568B2 (en) 1997-12-18
NZ275151A (en) 1998-02-26
BR9500380A (pt) 1995-10-17
RU2126404C1 (ru) 1999-02-20
IL112415A (en) 1999-07-14
FI950403A (sv) 1995-08-01

Similar Documents

Publication Publication Date Title
RU2736509C2 (ru) [9,10-диметокси-3-(2-метилпропил)-1h,2h,3h,4h,6h,7h,11bh- пиридо-[2,1-a]изохинолин-2-ил]метанол и связанные с ним соединения, композиции и способы
ES2297205T3 (es) Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica.
EP0843661B1 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate
EP0726893B1 (en) Novel 4-piperidinyl substituted lactames as neurokinin 2 receptor antagonists for the treatment of asthma
JPH08502511A (ja) ４−カルボキサミドピペリジン誘導体、中間体及びノイロキニンアンタゴニストとしての使用
SK20199A3 (en) Ether muscarinic antagonists
US5436255A (en) Method of treating diseases susceptable to treatment by blocking NMDA-receptors
FI113769B (sv) Neuroskyddande kromanföreningar
JP3498849B2 (ja) ニューロキニンａ拮抗剤としての二環式複素環化合物
US20090029979A1 (en) 5-htx modulators
US20120041026A1 (en) (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
EP0608336B1 (en) Azabicyclo arylacetylene and arylenyne oximes as cholinergic agents and methods of treatment
JP2010536713A (ja) キノロン化合物及び医薬組成物
WO2006010968A1 (en) New aryloxy acetic acid amide derivatives
US5710168A (en) 2-piperidino-1-alkanol derivatives as neuroprotective agents
EA011274B1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht
US5726188A (en) Optically active imidazolidinone derivatives and processes for preparing them
DE60112725T2 (de) Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
EP1565453A1 (en) 2- (4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
DE60033060T2 (de) Lineare oder zyklische Harnstoffe, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
Sonda et al. Synthesis and pharmacological evaluation of benzamide derivatives as selective 5-HT4 receptor agonists
CZ223896A3 (en) Condensation and addition polymers with n,n - bridge bis-tetramethylpiperidinyloxy groupings
KR100432841B1 (ko) 1-(4-히드록시페닐)-2-(4-히드록시-4-페닐피페리딘-1-일)-1-프로판올의 메실레이트염 삼수화물의 제조 방법 및 이에유용한 중간체
CZ20011471A3 (cs) Způsob přípravy mesylát-trihydrátové soli 1-(4-hydroxyfenyl)-2-(4-hydroxy-4-fenylpiperidin-1-yl)-1-propanolu
MXPA01007462A (en) Antidepressant heterocyclic compounds

Legal Events

Date Code Title Description
MA Patent expired